Drug Development

As pharma giants battle with blockbuster drugs, one company is betting on a simple, non-systemic hydrogel. Is this the future of weight management?

Nomic Bio and the HESI OASIS Consortium partner to map liver toxicity using proteomics, fueling AI models to make drug development safer and more ethical.

As MAPS announces its 2027 summit, the psychedelic field grapples with a critical question: can its visionary promise survive the harsh pressures of reality?

A new wave of disease-modifying therapies is poised to ignite the Huntington's disease market, projecting 14% annual growth and turning a field of despair into a high-stakes biotech race.

Biotech innovator Ernexa Therapeutics launches a new CEO platform, betting that open communication can help it solve cell therapy's biggest challenge: cost.

NeuroSense's PrimeC shows intriguing biomarker activity against Alzheimer's, targeting multiple disease pathways. Is this the shift away from single-target drugs?

Hatch BioFund's new investment in Princeton spinout Optimeos funds a novel nanoparticle platform that could solve one of medicine's biggest challenges.

A Virginia nonprofit's AI platform, backed by Pentagon funding, has decoded the deadly impact of radiation on the gut, paving the way for new countermeasures.

Positive Phase 3b data for Otsuka's centanafadine could revolutionize treatment for millions battling both ADHD and anxiety with a single, first-in-class drug.

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

A new partnership promises a less painful way to deliver cancer immunotherapy. We dive into the tech, the market, and why this is a key strategic play.

Lycia Therapeutics' oversubscribed $75M Series D validates its unique LYTAC platform, which aims to treat autoimmune diseases by destroying harmful proteins.

Professor Jason Chin’s Heinrich Wieland Prize signals a new era. His work in synthetic biology is enabling Constructive Bio to forge a new class of drugs.

With late-stage veterans on board, MRM Health isn't just advancing a drug; it's building the strategic architecture for microbiome's leap from lab to market.

Tiziana Life Sciences has dosed the final patient in a key trial for its nasal MS drug, foralumab. With data imminent, this could be a breakthrough for an untreatable form of the disease.

Promising 3-year survival data for a novel immunotherapy combo offers new hope for patients with MSS colorectal cancer, a notoriously difficult disease.

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

A landmark FDA approval for Merck's KEYTRUDA and Gilead's Trodelvy creates a powerful new first-line treatment for advanced triple-negative breast cancer.

Oblenio Bio's oversubscribed Series B will advance a novel tri-specific T-cell engager, aiming to reset the immune system without harsh side effects.